Search
Imdevimab
go.drugbank.com/drugs/DB15940ApprovedInvestigationalImdevimab is a monoclonal antibody combined with casirivimab in Regeneron's antibody cocktail known as REGEN-COV2 for the treatment of COVID-19. This drug is a combination of antibodies derived from humanized VelocImmune® mice in additio...
Upleganan
go.drugbank.com/drugs/DB21618InvestigationalUpleganan has a monoisotopic molecular weight of 1143.6 Da. … Upleganan is under investigation in clinical trial NCT04865393 (Phase 1 Study of PK and Safety of SPR206 in Subjects With Various Degrees Of Renal Function).
Thrombin alfa
go.drugbank.com/drugs/DB11572ApprovedThrombin Alfa is a human coagulation protein produced via recombinant DNA technology from a genetically modified CHO cell line. Thrombin Alfa is identical in amino acid sequence and structurally similar to naturally occurring human throm...
Cyclandelate
go.drugbank.com/drugs/DB04838ApprovedWithdrawnA direct-acting smooth muscle relaxant used to dilate blood vessels. It may cause gastrointestinal distress and tachycardia. Cyclandelate is not approved for use in the U.S. or Canada, but is approved in various European countries.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesOliceridine
go.drugbank.com/drugs/DB14881ApprovedInvestigational[A218026, A218031, A218051, A218056, A218061, A218066, A218071, L15516] Oliceridine was first reported in 2013,[A218026, A218086] but was initially not approved by the FDA due to concerns raised by … [A218031, A218046] However, due to the ability of some opioid agonists to bind to other targets, as well as activation of additional downstream pathways from opioid receptors such as those involving β-arrestin
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesBulevirtide
go.drugbank.com/drugs/DB15248ApprovedInvestigationalHepatitis D is considered the most severe type of viral hepatitis and leads to the rapid development of cirrhosis, severe decompensation of liver function, and an increased risk of mortality. … [L30260,L30275] Due to potentially beneficial synergistic effects in treating chronic Hepatitis D, bulevirtide is also under investigation in clinical trial NCT03852433 (Phase 2b Study of Bulevirtide With
Guanoxan
go.drugbank.com/drugs/DB13211ApprovedGuanoxan was approved in the UK but was withdrawn from the market due to hepatotoxicity. … Guanoxan is an antihypertensive agent similar in its mechanism of action to guanethidine; may cause liver damage.
Belumosudil
go.drugbank.com/drugs/DB16703ApprovedInvestigational[A236634] It is an inhibitor of rho-associated coiled-coil-containing protein kinases (ROCK), with significantly more selectivity for ROCK2 as compared to ROCK1 (IC<sub>50</sub> 100 nM vs. 3 μM, respectively … stem cell transplantation (HSCT), belumosudil helps to resolve immune dysregulation by shifting the balance between Th17 cells and T-regulatory cells, thereby dampening the inflammatory cascade that can
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesDoripenem
go.drugbank.com/drugs/DB06211ApprovedWithdrawnIn a clinical trial of doripenem treatment in ventilator associated pneumonia (vs. imipenem and cilastatin), it was found that doripenem carried an increased risk of death and lower clinical cure rates
Zonisamide
go.drugbank.com/drugs/DB00909ApprovedInvestigationalZonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures. … [L42530,L42535] Zonisamide represents an alternative for patients that remain refractory to established antiepileptic drugs. In 1989, it was approved for commercial use in Japan.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: Benzo[d]isoxazol-3-yl-methanesulfonamide